66
DAFTAR PUSTAKA
1. American Cancer Society. Cancer Facts & Figures 2013Atlanta, Ga:
American Cancer Society; 2013;5
2. Henley S.J, Singh S, King J, Wilson R, Ryeerson B, invasive cancer
Incidence – United States,2010. Center for Disease Control and
Prevention.2014.(63).12.253-258.
3. Pusat data dan informasi depkes RI. Profil kesehatan Indonesia
2008.Jakarta: Departemen kesehatan republik Indonesia
4. Profil Kesehatan Kota Semarang tahun 2009. Semarang: Dinas kesehatan
kota Semarang
5. Sarjadi, Trihartini, Pawitra I. Insiden kanker penduduk Semarang tahun
1990-1999. Semarang: Media Medika Indonesiana; 2001:36(1): 87-92
6. National comprehensive cancer network. NCCN Clinical Practice
Guidelines in Oncology (NCCN guidelines) Ver 3.2013. Washington; 2012
7. Pallis AG, Mouzas IA. Adjuvant chemotherapy for colon cancer (Review).
Anticancer research. 2006: 26: 4809-16
8. Johnson PW. A less toxic regimen of 5-fluorouracil and high-dose folinic
acid for advanced gastrointestinal adenocarcinomas. British journal cancer.
1991: 64: 603-5
67
9. Cassidy J, Twelves C, Van Cutsem E, et al: first-line capecitabine therapy
in metastatic colorectal cancer: a favourable safety profile compared with
intravenous 5-fluorouracil/leucoforin.Annals of oncology 2002:13:596-570.
10. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral
natural killer cells in gastric carcinoma. Cancer 2000;88: 577 – 83.
11. Agung BS, Faried A, Arifin MZ, Wiriadisastra K, Ohta T. Herbal Medicine
Isolation, Phaleria macrocarpa for primary glioblastoma multiforme cells.
Ann Epidemiol. 2008;18:708–41.
12. Riwanto I, Budijitno S, Dharmana E, Handojo D, Prasetyo SA, Eko A, et al.
Effect of phaleria macrocarpa supplementation on apoptosis and tumor
growth of C3H mice with breast cancer under treatment with adriamycin-
cyclophosphamide. Int Surg. 2011;96:164–70.
13. Zheng W, Gao X, Chen C, Tan R .Total flavonoids of daphne genkwa root
significantly inhibit the growth and metastasis of Lewis lung carsinoma in
C57BL6 mice.Int Immunopharmacol,2006:7(2): 117-27.
14. Budijitno S, Issakh B, Handojo D, Pudjonarko D, Riwanto I. Pengaruh
ekstrak mahkota dewa (Phaleria macrocarpa) terhadap skor ekspresi perforin
CTL dan sel-NK serta perkembangan massa tumor adenokarsinoma mamma
mencit C3H. M Med Indones J. 2007;42(3):37-40.
15. Sumastuti R, Sonlimar M. Efek sitotoksik ekstrak buah dan daun Phaleria
macrocarpa terhadap sel hepar. Yogyakarta: Farmakologi FK UGM;
2003:1-12.
68
16. Trapani JA. Granzymes: a family of lymphocyte granule serine proteases.
Protein Family Review.Genome Biology 2001:2(12).1-7.
17. Bots M, Madema JP. Granzymes at glance.Journal of cell science.
2006:119.5011-5014.
18. Agoes A. Mahkota dewa (Phaleria macrocarpa [scheff] boerl). In: Tanaman
obat Indonesia buku 2. Salemba Medika. 2010:71-3.
19. Faried, A., Kurnia, D., Faried, L.S., Usman, N., Miyazaki, T., Kato, H.,
Kuwano, H. Anticancer effects of gallic acid isolated from Indonesian
herbal medicine,Phaleria macrocarpa (Scheff.) Boerl on human cancer cell
lines. Int J Oncol. 2007: 30: 605-13.
20. Hiroko D, Teruhiko F, Shino N, Toshihiro K, Kazuo S. Analysis of cell
growth inhibitory effect of cathechin through MAPK in human breast
cancer cell line T47D. International Journal of Oncology. 2002: 21: 1301-5.
21. Kusmardiyani, S., Nawawi, A., Rahmi, K. Isolasi benzofenon dari daun
mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.]. Acta Pharmaceutica
Indonesia. 2004: 29: 150-2.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer
Statistics 2008. CA Cancer J Clin. 2011: 61: 69-90.
23. Parkin DM, Bray F, Ferlay J: Global Cancer Statistics 2002. CA Cancer J
Clin. 2011:55: 74-6.
24. Sjamsuhidajat R, Natawijana HA, Kartowisastro H. Faktor penyebab dan
resiko kanker usus besar. Semarang: Simposium upaya penemuan
keganasan usus besar secara dini; 19861-5.
69
25. Sinicrope FA, Hart J, Hsu H. Apoptotic and mitotic indices predict survival
rates in lymph node-negative colon carcinoma. Clinical Cancer Research.
1999: 1-5.
26. Wilkinson NW. Adjuvant chemotherapy for colorectal cancer - new
perspective for effective treatment. US gastroenterology review. 2007: 91-3.
27. Gordon PH, Nivatvongs S. 2007. Principles and practice of surgery for the
colon, rectum, and anus. 3rd ed. Informa Healthcare USA: New York. 1:2-
27.
28. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in
colorectal center. CA cancer J clin. 2009: 59: 366-378.
29. Mescher AL. 2010. Junqueira’s basic histology. 12th ed. Indiana: McGraw-
Hill education.5-25.
30. Zinner MJ, Ashley SW. 2011.Tumor of Colon. Maingot’s abdominal
operations. 11th ed. Boston: McGraw-Hill; 23.
31. Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews
JB, et al. 2010. Schwartz’s Principles of Surgery. 9th ed. Houston: McGraw-
Hill.28:733-783.
32. Rosai J. 2011. Rosai and Ackerman’s surgical pathology. 10th ed. Milan:
Mosby, London, UK, Elsevier;.(2) .2116.
33. Hamilton SR, Aaltonen LA. World Health Organization classification of
tumours: Pathology and genetics of tumours of the digestive system. Lyon:
IARC Press.2000:101-142.
70
34. Sobin LH, Wittekind CH. International Union Against Cancer UICC:
Classification of malignant tumours TNM. 7th ed. Oxford: A John Wiley &
Sons Inc. 2009; 27-28.
35. National comprehensive cancer network. NCCN Clinical Practice
Guidelines in Oncology (NCCN guidelines) Ver 3.2013. Washington; 2012
36. Kelompok kerja adenokarsinoma kolorektal Indonesia. Pengelolaan
karsinoma kolorektal: Suatu Panduan Klinis Nasional. Jakarta; 2004:1-51.
37. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of
colorectal cancer: Why we still don’t know. JAMA. 1988.259.3571-8.
38. Wilkinson NW. Adjuvant chemotherapy for colorectal cancer - new
perspective for effective treatment. US gastroenterology review. 2007: 91-3.
39. Naito Y, Saito K, Shiiba K, Ohuchi A, Saiqenji K, Naqura H, et al. CD8+ T
cells infiltrated within cancer cells nests as prognostic factor in human
colorectal cancer. Cancer Res. 1998; 58: 3491-4.
40. Ali AA, McMillan DC, Matulka II, McNicol AM, McArdel CS. Tumor T-
lymphocytes subset infiltration and tumour recurrence following curative
resection for colorectal cancer: Eur J Surg Oncol. 2004: 30: 292-5.
41. Kintzios SE, Maria G, Barberaki. Plants that fight cancer.Greece: CRC
Press LLC; 2004:125-7.
42. Abbas A, Lichtman AH, Pillai S. Cellular and molecular immunology. 6thed.
Philadelphia: Elsevier-Saunders; 2007: 4 - 15, 22 - 3, 65 - 80, 81 - 103, 182
- 7, 247 - 53, 258 - 9, 266, 268-9, 279-80, 290-5, 351–55,391-403.
71
43. Gorczynski R, Stanley J. Clinical Immunology. Georgetown, Texas: Landes
Bioscience. 1999: 337:53.
44. Jodi R, Viste, Sherry L, Myers, Singh B,Simko E. Feline mammary
adenocarcinoma: tumor size as a prognostic indicator. Can Vet J. 2002;
43(1).33: 7.
45. Kresno SB. 2003. Imunologi: diagnosis dan prosedur laboratorium edisi ke-
4. Balai Penerbit FKUI. Jakarta.208 : 24.
46. Karnen GB. 2006. Imunologi. 6th ed. Balai Penerbit FKUI. Jakarta. 222:7.
47. Restifo NP, Wunderlich JR. Cancer immunology. In: DeVita VT, Hellman
S, Steven AR. Cancer: principles and practice of oncology. 7th edition.
Philladelphia: Lippincott Williams & Wilkins; 2005: 140 – 58.
48. Killeen A. Principes of Moecular Pathology. New Jersey. Humana Press;
2004;202-207.
49. Berke G, Clark WR. Killer lymphocytes. Dordrecht, Netherland: Springer;
2005. 201 -216
50. Los M, Gibson SB. Apoptotic pathways as targets for novel therapies in
cancer and other diseases. New York: Springer; 2005.375-391
51. Martin AW. Immunohistology of non-Hodgkin lymphoma. In: Dabbs D.
Diagnostic immunohistochemistry 3rd ed. Philadelphia: Elsevier Saunders;
2010: 139 – 40, 167, 179.
52. Kumar, Abbas, Fausto, Mitchell. Robbins basic pathology 8th ed.
Philadelphia: Elsevier Saunders; 2007.
72
53. Trapani JA. Smyth M J. Functional Significance ofthe perforin/ granzyme
cell death pathway. Int J Immunol. 2002; 22 (2) : 735-47.
54. Adrain C, Creagh EM, Martin S J. Caspasecascades in apoptosis. In: Marek
Los, Henning Walczak. Editors. Caspases-their role in cell death and cell
survival. New York: Moleculare Biology Intelligence Unit 24; 2002: 41-51.
55. DenaultJB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem
Rev 2002:102(12): 4489-500.
56. Hendra R, Ahmad S, Oskoueian E, Sukari A, Shukor MY. Antioxidant, anti-
inflammatory and cytotoxicity of Phaleria macrocarpa (Boerl.) Scheff Fruit.
BMC Complementary and Alternative Medicine. 2011: 11: 110
57. Agoes A. Mahkota dewa (Phaleria macrocarpa [scheff] boerl). In: Tanaman
obat Indonesia buku 2. Salemba Medika. 2010:71-3.
58. Hendra R, Ahmad S, Oskoueian E, Sukari A, Shukor MY. Antioxidant, anti-
inflammatory and cytotoxicity of Phaleria macrocarpa (Boerl.) Scheff Fruit.
BMC Complementary and Alternative Medicine. 2011:11:110.
59. Wenzel U, Daniel H. Polyphenols and gene expression. In: Daayf F,
Lattanzio V, editors. Recent advances in polyphenols research. West
Sussex: Blackwell Publishing Ltd; 2008: 363-68.
60. Han X, Shen T, Lou H. Dietary Polyphenos and Their Biologica
Significance.Int. J. Mol. Sci.2007;8,950-988.
61. Bassalion, J.P., Scievella, A.R., dan Burns, E., Molec. Pharmacol., 56,
1999:359 – 369.
73
62. Jonker D, Spithoff K, Maroun J; Gastrointestinal cancer disease site group.
Adjuvant systemic chemotherapy for stage II and III colon cancer following
complete resection. Toronto: Cancer care Ontario; 2008 Apr 17 [In review
2011 Sep]. Program in evidence-based care evidence-based series : 2-29.
63. Andre T, O’neil BH, Meyerhardt JA. Stage III Kolon Cancer : What works,
what doesn’t and why, and what’s next. American Society of Clinical
Oncology. 2012:10:223-30.
64. Govindan R, Arquette MA, Washington manual of oncology. Washington:
Lippincott Williams and Wilkins; 2002:192-202.
65. Chu E, DeVita VT. Physicians’ cancer chemotherapy drug manual 2010.
Massachusetts: Jones and Bartlett Publishers; 2010:183-8.
66. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et
al. Leucovorin and fluorouracil without oxaliplatin as first-line treatment in
advanced colorectal cancer. American society of clinical oncology. Journal
of clinical oncology. 2000:18;16.
67. 1,2 Dimethylhydrazine. IARC Monographs Vol 71. 1087: 958-61
68. Joseph CA, Woo YT, Argus MF. Chemical of cancer. London: Academic
Press; 1982:350-93.
69. Nauss KM, Lockniskir M, Pavlina T, Newbere PM. Morphology and
distribution of 1,2-Dimethylhidrazine-induced colon tumor and their
relationship to gut-associated lymphoid tissue in the rat. J Natl Cancer Inst.
1984:73: 915-24.
74
70. Samiasih A. Perbedaan ekspresi VEGF sel adenokarsinoma kolorektal tikus
Sprague Dawley dengan dan tanpa pemberian ekstrak Phyllantus niruri.
Semarang: Magister ilmu biomedik program pasca sarjana Universitas
Diponegoro; 2010;24-33.
71. D. C. Bicknell, A . Rowan, and W. F. Bodmer, “ ß2Mi crog lobulin gene
mutations: a study of established colorectal cell lines and fresh tumors,”
Proceeding s of the Nat i onal Ac ade my of Sc ie nces of the United States
of Ame r i ca: 1994.vol. 91, 4751–4755
72. Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive
analysis of the percentage of surface receptors and cytotoxic granules
positive natural killer cells in patients with pancreatic cancer, gastric cancer,
and colorectal cancer. J Transl Med (2013) 11:262.10.1186/1479-5876-11-
262
75
LAMPIRAN
LAMPIRAN 1 : PERHITUNGAN DOSIS KONVERSI
1,2 Dimethylhidrazine
Dosis 30 mg/kgBB/minggu
Berat 20 gram = 6mg/ekor/minggu
Jumlah pemberian 16 kali
TOTAL = 16 kali x 6 mg x 40 ekor = 3.840 mg
5FU-Leucovorin (Rosswell Park Regiment)
Dosis pemberian kemoterapi (Konstanta konversi = 0.018)
BSA Tikus : BB Tikus = 200 gram = 0,2 kg - Panjang Badan Tikus : 20 cm
BSA = 10.5 (wt. in grams)2/3 = 0.03 m2
Dosis Leucovorin pada Tikus = 500 mg/m2 x 0.018 x 0.03 m2 = 0.27 mg
Dosis 5FU pada Tikus = 500 mg/m2 x 0.018 x 0.03 m2 = 0.27 mg
P. macrocarpa
Dosis ekstrak = 0.495 mg/hari
Konsentrasi larutan = 0.495 mg/ml
Jumlah tikus = 16 ekor
Lama perlakuan = 49 hari
Kebutuhan ekstrak Phaleria macrocarpa = 0.495 mg/ekor/hr x 16 ekor x 49 hari = 388.08 mg =784 cc
76
LAMPIRAN 2. HASIL PENGAMATAN DENSITAS SEL NK DAN EKSPRESI
GRANZYM B
Tabel 9: Tabulasi data densitas Sel NK
Kel La1 La2 La3 La4 La5 Rataa Lb1 Lb2 Lb3 Lb4 Lb5 ratab rataNK
K 1 6 4 6 5 6 5.4 6 6 6 5 6 5.8 5.6
K 2 5 6 5 4 6 5.2 6 4 6 5 6 5.4 5.3
K 3 6 6 5 3 5 5 5 6 6 6 5 5.6 5
K 4 4 4 5 6 5 4.8 4 5 7 6 5 5.4 5.1
K 5 4 5 4 5 4 4.4 5 4 4 5 4 4.4 4.4
K 6 6 7 6 6 7 6.4 7 6 5 6 7 6.2 6.3
P1 1 10 7 10 10 8 9 8 9 10 10 8 9 9
P1 2 8 9 8 6 10 8.2 9 9 8 7 10 8.6 8.4
P1 3 8 8 8 8 8 8 9 8 7 8 8 8.8 8
P1 4 8 8 10 8 8 8.4 8 9 9 10 9 9 8.7
P1 5 9 10 8 8 10 9 8 10 8 8 9 8.6 8.8
P1 6 10 9 10 8 10 9.4 10 9 9 8 10 9.2 9.3
Tabel 10: Tabulasi data ekspresi granzym B
Kel La1 La2 La3 La4 La5 Rataa Lb1 Lb2 Lb3 Lb4 Lb5 ratab rataGR
K 1 10 8 11 10 8 9.4 10 9 10 9 9 9.4 9.4
K 2 12 12 11 9 10 10.8 11 12 10 11 10 10.8 10.8
K 3 12 10 10 8 10 10 11 10 10 9 10 10 10
K 4 10 10 10 12 12 10.8 11 10 11 11 11 10.8 10.8
K 5 9 11 11 10 9 10 9 11 11 10 9 10 10
K 6 11 9 10 11 11 10.4 12 9 10 11 10 10.4 10.4
P1 1 14 12 8 10 13 11.4 14 11 9 11 12 11.4 11.4
P1 2 12 10 10 14 10 11.2 12 11 10 13 10 11.2 11.2
P1 3 10 12 12 10 10 10.8 11 11 12 10 10 10.8 10.8
P1 4 12 10 13 10 11 11.2 12 12 13 12 11 11.2 11.2
P1 5 12 10 14 12 11 11.8 12 11 13 11 12 11.8 11.8
P1 6 13 12 10 12 12 11.8 12 12 11 13 11 11.8 11.8
77
LAMPIRAN 3. FOTO PENELITIAN
Gambar 12. Gambar hewan coba sedang diinduksi 1,2-dimethylhidrazine (kanan)
Gambar 13. Gambar hewan coba sedang mendapat perlakuan (kiri)
Gambar 14. Gambaran makroskopis adenokarsinoma kolorektalyang sudah diisolasi ( kanan dan kiri)
78
LAMPIRAN 4. ANALISIS STATISTIK
SEL NATURAL KILLER
Case Processing Summary
Cases
Included Excluded Total
N Percent N Percent N Percent
Sel_NK * Kelompok 12 100.0% 0 .0% 12 100.0%
EXPLORE
RATA DENSITAS SEL_NK
Kelompok N Mean Median Minimum Maximum Sum Variance Std. Deviation
Kontrol 6 5.283 5.200 4.4 6.3 31.7 .406 .6369
P1 6 8.700 8.750 8.0 9.3 52.2 .208 .4561
Total 12 6.992 7.150 4.4 9.3 83.9 3.463 1.8608
Tests of Normality
Kelompok
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic Df Sig.
Sel_NK Kontrol .162 6 .200* .977 6 .936
P1 .167 6 .200* .987 6 .980
a. Lilliefors Significance Correction
*. This is a lower bound of the true significance.
Test of Homogeneity of Variance
Levene Statistic df1 df2 Sig.
Sel_NK Based on Mean .344 1 10 .570
Based on Median .328 1 10 .579
Based on Median and with
adjusted df
.328 1 8.765 .581
Based on trimmed mean .344 1 10 .571
79
RATA –RATA DENSITAS SEL NK KELOMPOK KONTROL
RATA –RATA DENSITAS SEL NK KELOMPOK PERLAKUAN
.
80
BOX PLOT KELOMPOK KONTROL DAN PERLAKUAN
UJI KOMPARASI DENGAN INDEPENDENT T TESTLevene's Test for Equality of Variances t-test for Equality of Means
95% Confidence Interval of the
Difference
F Sig. t dfSig. (2-tailed)
Mean Difference
Std. Error Difference Lower Upper
Sel_NK Equal variances assumed .344 .570 -10.683 10 .000 -3.4167 .3198 -4.1292 -2.7041
Equal variances not assumed -10.683 9.060 .000 -3.4167 .3198 -4.1394 -2.6939
81
GRANZYM B
Case Processing Summary
Cases
Included Excluded Total
N Percent N Percent N Percent
Granzyme_B * Kelompok 12 100.0% 0 .0% 12 100.0%
EXPLORE
.
Tests of Normality
Kelompok
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Granzyme_B Kontrol .185 6 .200* .913 6 .459
P1 .201 6 .200* .912 6 .452
a. Lilliefors Significance Correction
*. This is a lower bound of the true significance.
Test of Homogeneity of Variance
Levene Statistic df1 df2 Sig.
Granzyme_B Based on Mean .952 1 10 .352
Based on Median .899 1 10 .365
Based on Median and with
adjusted df
.899 1 9.648 .366
Based on trimmed mean .950 1 10 .353
RATA EKSPRESI GRANZYM B
Kelompok N Mean Median Minimum Maximum Sum Variance Std. Deviation
Kontrol 6 10.233 10.200 9.4 10.8 61.4 .295 .5428
P1 6 11.367 11.300 10.8 11.8 68.2 .151 .3882
Total 12 10.800 10.800 9.4 11.8 129.6 .553 .7435
82
RATA –EKSPRESI GRANZYM B KELOMPOK KONTROL
RATA –EKSPRESI GRANZYM B KELOMPOK PERLAKUAN
83
BOX PLOT KELOMPOK KONTROL DAN PERLAKUAN
UJI KOMPARASI DENGAN INDEPENDENT T TESTLevene's Test for Equality of
Variances t-test for Equality of Means
95% Confidence
Interval of the Difference
F Sig. t dfSig. (2-tailed)
Mean Difference
Std. Error Difference Lower Upper
Granzyme_B Equal variances assumed .952 .352 -4.160 10 .002 -1.1333 .2724 -1.7404 -.5263
Equal variances not assumed
-4.160 9.053 .002 -1.1333 .2724 -1.7491 -.5176
UJI KORELASI DENGAN UJI PEARSON
Sel_NK Granzyme_B
Sel_NK Pearson Correlation 1 .819**
Sig. (2-tailed) .001
N 12 12
Granzyme_B Pearson Correlation .819** 1
Sig. (2-tailed) .001
N 12 12
**. Correlation is significant at the 0.01 level (2-tailed).
84
LAMPIRAN 5. ETHICAL CLEARANCE